论文部分内容阅读
目的探讨化疗联合自体细胞因子诱导的杀伤细胞(cytokine-induced killer,CIK)治疗晚期非小细胞肺癌(nonsmall cell lung cancer,NSCLC)的临床疗效及安全性。方法Ⅲa~Ⅳ期NSCLC患者72例,行单纯化疗(多西他赛+顺铂)36例为对照组,行化疗联合自体CIK细胞免疫治疗36例为观察组,治疗2个周期评定疗效,随访观察2组无进展生存期、总生存期和安全性。结果观察组疾病控制率(77.8%)高于对照组(52.8%)(P<0.05),中位无进展生存期及总生存期(9个月,19个月)较对照组(6个月,10个月)明显延长(P<0.05);2组疾病总缓解率(33.3%vs 25.0%)比较差异无统计学意义(P>0.05);观察组1、2a生存率分别为58.3%、30.6%,对照组分别为33.3%、8.6%,2组比较差异有统计学意义(P<0.05);观察组治疗后Ⅲ~Ⅳ度骨髓抑制、恶心发生率(8.3%,33.3%)低于对照组(30.6%,61.1%)(P<0.05)。结论化疗联合自体CIK细胞免疫治疗NSCLC安全性好,可延缓疾病进展,延长患者生存时间。
Objective To investigate the clinical efficacy and safety of chemotherapy combined with cytokine-induced killer (CIK) in the treatment of advanced non-small cell lung cancer (NSCLC). Methods A total of 72 patients with stage Ⅲa-Ⅳ NSCLC were treated with chemotherapy (docetaxel + cisplatin) in 36 cases. The patients received chemotherapy and autologous CIK cell immunotherapy in 36 cases. The therapeutic effect was evaluated after 2 cycles of follow-up The progression-free survival, overall survival and safety of the two groups were observed. Results The rate of disease control in the observation group (77.8%) was higher than that in the control group (52.8%) (P <0.05). The median progression-free survival and overall survival (9 months and 19 months) , 10 months) (P <0.05). There was no significant difference in the total remission rate between two groups (33.3% vs 25.0%) (P> 0.05) 30.6% in the control group and 33.3% in the control group, 8.6% in the control group respectively (P <0.05). The degree of myelosuppression in Ⅲ ~ Ⅳ degree group was lower than that in the observation group (8.3%, 33.3% Control group (30.6%, 61.1%) (P <0.05). Conclusion Chemotherapy combined with autologous CIK cell immunotherapy NSCLC is safe and can delay the disease progression and prolong the survival time of patients.